PCRX Pacira BioSciences, Inc.
Stock · NasdaqGS · United States · Healthcare · US6951271005
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Pacira BioSciences, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
36.43 USD
+0.03%
52-week range
18.80 – 36.67
Dividend yield—
Market cap1.5B
NowoTrade score
24 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:54. Information, not advice.
Results
Next results
25 Feb 2027
in 109 days · 16:00 · estimate 0.83
Last results
0.70 vs 0.15 estimated
05 Nov 2026 · Beat +366.7%
Beat the estimate
10 of 12
1 missed · 1 in line · 3 beats in a row
Average surprise
+34.6%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 16:00 | 0.83 | — | — | Upcoming |
| 05 Nov 2026 16:00 | 0.15 | 0.70 | +366.7% | Beat |
| 04 Aug 2026 16:00 | 0.65 | 0.73 | +12.8% | Beat |
| 30 Apr 2026 16:00 | 0.56 | 0.60 | +6.4% | Beat |
| 26 Feb 2026 16:00 | 0.90 | 0.57 | -37.0% | Miss |
| 06 Nov 2025 16:00 | 0.65 | 0.70 | +7.4% | Beat |
| 05 Aug 2025 16:00 | 0.71 | 0.74 | +4.2% | Beat |
| 08 May 2025 16:00 | 0.60 | 0.62 | +3.8% | Beat |
| 27 Feb 2025 16:00 | 0.83 | 0.91 | +9.6% | Beat |
| 06 Nov 2024 16:00 | 0.70 | 0.79 | +12.1% | Beat |
| 30 Jul 2024 16:00 | 0.70 | 0.89 | +27.3% | Beat |
| 07 May 2024 16:00 | 0.62 | 0.62 | -0.7% | In line |
| 29 Feb 2024 08:00 | 0.87 | 0.89 | +2.2% | Beat |
| 02 Nov 2023 08:00 | 0.78 | 0.72 | -7.8% | Miss |
| 02 Aug 2023 08:00 | 0.76 | 0.78 | +2.9% | Beat |
| 03 May 2023 08:00 | 0.62 | 0.53 | -14.2% | Miss |
| 28 Feb 2023 08:00 | 0.83 | 0.80 | -3.4% | Miss |
| 03 Nov 2022 08:00 | 0.76 | 0.64 | -16.3% | Miss |
| 03 Aug 2022 08:00 | 0.85 | 0.51 | -40.2% | Miss |
| 04 May 2022 08:00 | 0.83 | 0.64 | -23.1% | Miss |
| 24 Feb 2022 08:00 | 0.83 | 0.97 | +16.8% | Beat |
| 03 Nov 2021 08:00 | 0.65 | 0.72 | +10.2% | Beat |
| 03 Aug 2021 08:00 | 0.74 | 0.77 | +4.7% | Beat |
| 04 May 2021 08:00 | 0.63 | 0.53 | -16.0% | Miss |
| 25 Feb 2021 08:00 | 0.81 | 0.87 | +6.9% | Beat |
| 29 Oct 2020 08:00 | 0.65 | 0.68 | +4.4% | Beat |
| 06 Aug 2020 08:00 | 0.09 | 0.12 | +29.4% | Beat |
| 07 May 2020 08:00 | 0.30 | 0.53 | +77.9% | Beat |
| 20 Feb 2020 08:00 | 0.44 | 0.56 | +27.6% | Beat |
| 07 Nov 2019 08:00 | 0.33 | 0.48 | +47.5% | Beat |
| 08 Aug 2019 08:00 | 0.34 | 0.41 | +20.7% | Beat |
| 02 May 2019 08:00 | 0.26 | 0.22 | -13.9% | Miss |
| 28 Feb 2019 08:00 | 0.29 | 0.47 | +60.9% | Beat |
| 01 Nov 2018 08:00 | 0.08 | 0.31 | +284.3% | Beat |
| 02 Aug 2018 08:00 | 0.07 | 0.24 | +245.6% | Beat |
| 03 May 2018 08:00 | 0.03 | 0.02 | -24.2% | Miss |
| 28 Feb 2018 08:00 | 0.09 | 0.38 | +312.9% | Beat |
| 08 Nov 2017 07:00 | -0.07 | 0.11 | +265.0% | Beat |
| 02 Aug 2017 07:00 | -0.05 | -0.11 | -127.6% | Miss |
| 04 May 2017 08:00 | -0.02 | -0.19 | -770.8% | Miss |
| 01 Mar 2017 07:00 | 0.01 | 0.09 | +631.1% | Beat |
| 02 Nov 2016 07:00 | -0.04 | 0.20 | +660.1% | Beat |
| 04 Aug 2016 07:00 | 0.05 | 0.19 | +303.3% | Beat |
| 02 May 2016 07:00 | 0.11 | 0.14 | +33.3% | Beat |
| 25 Feb 2016 07:00 | 0.27 | 0.20 | -26.2% | Miss |
| 27 Oct 2015 07:00 | 0.15 | 0.32 | +113.3% | Beat |
| 30 Jul 2015 07:00 | 0.23 | 0.20 | -13.0% | Miss |
| 30 Apr 2015 06:00 | 0.21 | 0.23 | +10.1% | Beat |
| 24 Feb 2015 06:00 | 0.27 | 0.35 | +30.7% | Beat |
| 30 Oct 2014 06:00 | 0.10 | 0.14 | +40.0% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 726.4M | +3.6% | 7M | 1.0% | 0.16 | +107.4% | 136.7M |
| 2024 | 701M | +3.9% | -99.6M | -14.2% | -2.15 | -341.6% | 178.8M |
| 2023 | 675M | +1.2% | 42M | 6.2% | 0.89 | +161.8% | 139.5M |
| 2022 | 666.8M | — | 15.9M | 2.4% | 0.34 | — | 115.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 10 Jun 2024 – 14 Jun 2024 | 28.06 | 29.95 | 27.58 | 28.13 | -1.54% | 3,573,500 | |
| 03 Jun 2024 – 07 Jun 2024 | 30.47 | 31.64 | 28.39 | 28.57 | -5.80% | 2,727,300 | |
| 28 May 2024 – 31 May 2024 | 29.76 | 30.99 | 28.91 | 30.33 | +2.16% | 2,327,300 | |
| 20 May 2024 – 24 May 2024 | 30.70 | 31.27 | 29.67 | 29.69 | -3.67% | 2,792,400 | |
| 13 May 2024 – 17 May 2024 | 29.79 | 31.67 | 29.79 | 30.82 | +4.76% | 4,344,300 | |
| 06 May 2024 – 10 May 2024 | 27.45 | 30.70 | 26.43 | 29.42 | +8.12% | 11,421,400 | |
| 29 Apr 2024 – 03 May 2024 | 26.42 | 27.77 | 25.44 | 27.21 | +3.34% | 2,058,000 | |
| 22 Apr 2024 – 26 Apr 2024 | 26.19 | 27.09 | 25.33 | 26.33 | +0.30% | 1,842,200 | |
| 15 Apr 2024 – 19 Apr 2024 | 26.89 | 27.63 | 25.76 | 26.25 | -2.16% | 2,812,500 | |
| 08 Apr 2024 – 12 Apr 2024 | 28.10 | 28.84 | 26.61 | 26.83 | -4.72% | 1,930,400 | |
| 01 Apr 2024 – 05 Apr 2024 | 29.44 | 29.47 | 27.94 | 28.16 | -3.63% | 1,938,900 | |
| 25 Mar 2024 – 28 Mar 2024 | 28.87 | 29.58 | 28.25 | 29.22 | +1.92% | 2,041,100 | |
| 18 Mar 2024 – 22 Mar 2024 | 29.42 | 30.39 | 28.44 | 28.67 | -2.52% | 1,787,600 | |
| 11 Mar 2024 – 15 Mar 2024 | 30.98 | 31.46 | 28.82 | 29.41 | -6.37% | 2,776,400 | |
| 04 Mar 2024 – 08 Mar 2024 | 28.40 | 31.47 | 27.89 | 31.41 | +8.84% | 2,924,200 | |
| 26 Feb 2024 – 01 Mar 2024 | 29.97 | 30.52 | 28.61 | 28.86 | -3.93% | 2,820,600 | |
| 20 Feb 2024 – 23 Feb 2024 | 28.86 | 30.34 | 28.86 | 30.04 | +3.30% | 1,408,200 | |
| 12 Feb 2024 – 16 Feb 2024 | 28.92 | 30.04 | 28.92 | 29.08 | +1.04% | 1,928,900 | |
| 05 Feb 2024 – 09 Feb 2024 | 30.08 | 31.48 | 27.37 | 28.78 | -5.14% | 4,103,000 | |
| 29 Jan 2024 – 02 Feb 2024 | 32.02 | 34.01 | 30.14 | 30.34 | -5.34% | 3,282,300 | |
| 22 Jan 2024 – 26 Jan 2024 | 32.13 | 32.96 | 31.63 | 32.05 | +0.66% | 1,471,700 | |
| 16 Jan 2024 – 19 Jan 2024 | 32.25 | 32.51 | 31.10 | 31.84 | -1.21% | 1,497,100 | |
| 08 Jan 2024 – 12 Jan 2024 | 34.29 | 35.95 | 31.00 | 32.23 | -5.95% | 2,965,900 | |
| 02 Jan 2024 – 05 Jan 2024 | 33.48 | 34.86 | 31.34 | 34.27 | +1.57% | 2,141,000 | |
| 26 Dec 2023 – 29 Dec 2023 | 33.26 | 34.52 | 32.92 | 33.74 | +2.09% | 1,772,200 |
Page 6 of 11
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Pacira BioSciences Withdraws 2026 Guidance Pending Proposed Merger With Viatris (opens in a new tab) Benzinga · 05 Nov 2026 17:45
- Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth (opens in a new tab) Zacks · 29 Oct 2026 13:00
- Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing (opens in a new tab) Simply Wall St. · 23 Oct 2026 17:13
- Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus (opens in a new tab) Stocktwits · 12 Oct 2026 07:32
- Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says (opens in a new tab) MT Newswires · 09 Oct 2026 16:23
- Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio (opens in a new tab) Zacks · 09 Oct 2026 14:37
- Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus (opens in a new tab) Simply Wall St. · 09 Oct 2026 07:09
- Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly (opens in a new tab) Investor's Business Daily · 08 Oct 2026 21:20
- Viatris to acquire Pacira BioSciences for $1.65 billion (opens in a new tab) Quartz · 08 Oct 2026 19:31
- Why Is Viatris (VTRS) Expanding Its Non Opioid Pain Portfolio Now? (opens in a new tab) Simply Wall St. · 08 Oct 2026 19:08
- HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today? (opens in a new tab) Stocktwits · 08 Oct 2026 18:48
- Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition (opens in a new tab) Barrons.com · 08 Oct 2026 18:29
- Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout (opens in a new tab) Pharmaceutical Technology · 08 Oct 2026 18:20
- Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal (opens in a new tab) MT Newswires · 08 Oct 2026 17:02
- Viatris boosts pain drug portfolio with $1.7B buyout of Pacira (opens in a new tab) BioPharma Dive · 08 Oct 2026 17:00
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 36.42 USD
- Market cap
- 1.5B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 2.4 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 1.6 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 13.3 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 10.2 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 0.7 / 10 |
|
- Thin interest cover: operating profit is only 1.3× the interest
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 39.17× | Weak | 30.65× |
| P/E (forward) | 10.53× | Good | 14.89× |
| Price / book | 2.04× | Fair | 3.8× |
| Price / sales | 1.96× | Good | 3.19× |
| EV / EBITDA | 12.61× | Fair | 12.61× |
| Free cash flow yield | 13% | Good | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 78% | Good | 58.6% |
| Operating margin | 9.4% | Fair | 7.6% |
| Net margin | 5.1% | Fair | 2.7% |
| Return on equity | 5.2% | Weak | 5.7% |
| Return on assets | 1.5% | Weak | 3.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 2.9% | Weak | 10.8% |
| EPS growth / year | -22.2% | Weak | 9.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.48× | Good | 0.48× |
| Net debt / EBITDA | 0.37× | Good | 1.6× |
| Interest cover | 1.31× | Weak | 2.65× |
| Current ratio | 4.68× | Good | 2.36× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow PCRX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.